Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.34 |
| ▸ | PTPRB | P23467 | 2/20 | 0.34 |
| ▸ | PTPRE | P23469 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | RAB7A | P51149 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7693899 | 0.81 | PTPN1 (0.53) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL7854135 | 0.80 | PTPN1 (0.58) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL7536578 | 0.77 | PTPN1 (0.38) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL4449756 | 0.77 | PTPN1 (0.55) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL27558196 | 0.75 | PTPN1 (0.43) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL6402782 | 0.75 | PTPN1 (0.57) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL6399832 | 0.75 | PTPN1 (0.39) | PTPN1PTPRCPTPN2PTPRBPTPRE | |
| SCHEMBL7855098 | 0.74 | PTPN2 (0.58) | PTPN1PTPN2KMT2ANOD1POLB | |
| SCHEMBL6394168 | 0.73 | PTPN1 (0.36) | PTPN1PTPN2PTPRBRAB7A | |
| SCHEMBL7540375 | 0.72 | PTPN1 (0.62) | PTPN1PTPRCPTPN2PTPRBPTPRE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-02-14 | — | — | US | claimed |
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-02-14 | — | — | US | disclosed |
| EP-1062218-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046268-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | PTPRCAP, PTPRS, PTPRA | PTPN1 7/4885PTPRC 6/4885PTPN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.